Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171431 · ClinicalTrials.gov registry record · Phase 3
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00171431 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT00171431, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171431
The ClinicalTrials.gov registry entry for NCT00171431 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00171431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00171431 about?
NCT00171431 is a clinical study titled "The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)". Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.
What is the current status of trial NCT00171431?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2004-11. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00171431?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00171431?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.